Cancers, Vol. 15, Pages 4115: Zoledronic Acid Prevents Bone Resorption Caused by the Combination of Radium-223, Abiraterone Acetate, and Prednisone in an Intratibial Prostate Cancer Mouse Model
In conclusion, radium-223/abiraterone/prednisone combination increased bone resorption, which may have been one of the mechanisms leading to an increased fracture risk in patients with mCRPC. (Source: Cancers)
Source: Cancers - August 15, 2023 Category: Cancer & Oncology Authors: Mari I. Suominen Matias Knuuttila Birgitta Sj öholm Timothy Wilson Esa Alhoniemi Dominik Mumberg Sanna-Maria K äkönen Arne Scholz Tags: Article Source Type: research
Effect of Food and Polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on Pharmacokinetics of Abiraterone and its Metabolites in Chinese Volunteers
CONCLUSIONS: Polymorphisms in SLCO2B1 were significantly related to the PK variability of ABI and its metabolites under both fasted and fed conditions.PMID:37574850 | DOI:10.1111/bcp.15883 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Yixin Hu Jianyuan Wu Bingyu Cheng Rongli You Xueyan Yin Guiying Chen Ling Yang Yang Zhang Luqin Si Hongliang Jiang Yongjun Zhang Jianying Huang Jiangeng Huang Source Type: research
Effect of Food and Polymorphisms in SLCO2B1, CYP3A4 and UGT1A4 on Pharmacokinetics of Abiraterone and its Metabolites in Chinese Volunteers
CONCLUSIONS: Polymorphisms in SLCO2B1 were significantly related to the PK variability of ABI and its metabolites under both fasted and fed conditions.PMID:37574850 | DOI:10.1111/bcp.15883 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - August 14, 2023 Category: Cancer & Oncology Authors: Yixin Hu Jianyuan Wu Bingyu Cheng Rongli You Xueyan Yin Guiying Chen Ling Yang Yang Zhang Luqin Si Hongliang Jiang Yongjun Zhang Jianying Huang Jiangeng Huang Source Type: research
OncoFlash – Research Updates in a Flash! (Sept 2023)
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. Chi KN et al. J Clin Oncol. 2023 [1] (Source: Clinical Oncology)
Source: Clinical Oncology - August 12, 2023 Category: Radiology Authors: C. Lorimer, K.T. Jayaprakash Source Type: research
An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer
Expert Opin Pharmacother. 2023 Aug 7:1-10. doi: 10.1080/14656566.2023.2244415. Online ahead of print.ABSTRACTINTRODUCTION: Prostate cancer is the most common malignancy in the male. Androgen-deprivation therapy (ADT) has been the mainstay in the treatment of metastatic prostate cancer however, due to the outgrowth of castration-resistant cell population the disease inevitably progresses to an aggressive, difficult to handle stage.AREAS COVERED: We have reviewed the literature regarding hormonal-directed therapy prostate cancer. New agents, namely abiraterone acetate, combined with prednisone, and next generation antiandrog...
Source: Expert Opinion on Pharmacotherapy - August 7, 2023 Category: Drugs & Pharmacology Authors: Maria Mitsogianni Athanasios Papatsoris Vanessa-Meletia Bala Hussein Issa Mohammad Moussa Iraklis Mitsogiannis Source Type: research
Cardiovascular Adverse Events Associated With New-Generation Androgen Receptor Pathway Inhibitors (ARPI) for Prostate Cancer: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)
CONCLUSION: Abiraterone acetate and apalutamide presumably are associated with a higher risk of MACE than enzalutamide in new-generation ARPI for prostate cancer. More extensive prospective studies and more extended follow-up periods need to confirm this further.PMID:37482524 | DOI:10.1016/j.clgc.2023.07.003 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 23, 2023 Category: Cancer & Oncology Authors: Yang Liu Hui-Min Zhang Yu Jiang Zhi Wen Er-Hao Bao Jing Huang Chong-Jian Wang Cai-Xia Chen Jia-Hao Wang Xue-Song Yang Source Type: research
Association between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials
Prostate Cancer and Prostatic Diseases, Published online: 18 July 2023; doi:10.1038/s41391-023-00695-xAssociation between concomitant proton pump inhibitor use and survival of patients with metastatic prostate cancer receiving abiraterone acetate: a post-hoc analysis of pooled data from three randomized controlled trials (Source: Prostate Cancer and Prostatic Diseases)
Source: Prostate Cancer and Prostatic Diseases - July 18, 2023 Category: Urology & Nephrology Authors: Wataru Fukuokaya Keiichiro Mori Takafumi Yanagisawa Kohei Akazawa Tatsuya Shimomura Takahiro Kimura Source Type: research
Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
CONCLUSION: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.PMID:37439809 | DOI:10.1158/1078-0432.CCR-23-0731 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 13, 2023 Category: Cancer & Oncology Authors: Neil E Fleshner Rashid K Sayyid Aaron R Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala Sridhar Madeleine Mouss Source Type: research
Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
CONCLUSION: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.PMID:37439809 | DOI:10.1158/1078-0432.CCR-23-0731 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 13, 2023 Category: Cancer & Oncology Authors: Neil E Fleshner Rashid K Sayyid Aaron R Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala Sridhar Madeleine Mouss Source Type: research
Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
CONCLUSION: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.PMID:37439809 | DOI:10.1158/1078-0432.CCR-23-0731 (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 13, 2023 Category: Cancer & Oncology Authors: Neil E Fleshner Rashid K Sayyid Aaron R Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala Sridhar Madeleine Mouss Source Type: research
Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
CONCLUSION: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.PMID:37439809 | DOI:10.1158/1078-0432.CCR-23-0731 (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 13, 2023 Category: Cancer & Oncology Authors: Neil E Fleshner Rashid K Sayyid Aaron R Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala Sridhar Madeleine Mouss Source Type: research
Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
CONCLUSION: Our systematic development of the abiraterone PBPK model has demonstrated its application for the prospective interrogation of the individual or combined influences of potential interindividual variabilities influencing the systemic exposure of abiraterone.PMID:37405634 | DOI:10.1007/s40262-023-01266-y (Source: Clinical Prostate Cancer)
Source: Clinical Prostate Cancer - July 5, 2023 Category: Cancer & Oncology Authors: Eleanor Jing Yi Cheong Sheng Yuan Chin Zheng Wei Ng Ting Jian Yap Ervin Zhi Bin Cheong Ziteng Wang Eric Chun Yong Chan Source Type: research
Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
ConclusionOur systematic development of the abiraterone PBPK model has demonstrated its application for the prospective interrogation of the individual or combined influences of potential interindividual variabilities influencing the systemic exposure of abiraterone. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - July 5, 2023 Category: Drugs & Pharmacology Source Type: research
